The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
Dong-Wan Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Myung-Ju Ahn
No relevant relationships to disclose
Yuankai Shi
No relevant relationships to disclose
Tommaso Martino De Pas
No relevant relationships to disclose
Pan-Chyr Yang
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - Abbott Molecular; ARIAD; Chugai Pharma; Daiichi Sankyo; Tragara Pharmaceuticals (U)
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck Serono; Pfizer
Lucio Crinò
Honoraria - ECCO-ESMO
Tracey L. Evans
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Ji-Youn Han
No relevant relationships to disclose
Ravi Salgia
No relevant relationships to disclose
Denis Moro-Sibilot
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Other Remuneration - Pfizer
Sai-Hong Ignatius Ou
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Scott N. Gettinger
Research Funding - Pfizer
Yi Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
Silvana Lanzalone
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Anna Polli
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Shrividya Iyer
Employment or Leadership Position - Pfizer
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Pfizer
Honoraria - Millennium; Novartis
Research Funding - ARIAD; AstraZeneca; Novartis; Pfizer